Edit

Cortexyme, Inc.

http://www.cortexyme.com/

Last activity: 09.12.2021

Active

Categories: BioTechCauseDevelopmentFamilyLifeMedtechMovingPlatform

Cortexyme is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer’s and other degenerative diseases. Cortexyme is targeting a specific pathogen found in the brain of Alzheimer’s patients that causes neurodegeneration and other pathology in animal models. Cortexyme’s lead small molecule, atuzaginstat (COR388), has advanced through Phase Ib and is currently the subject of a Phase 2/3 GAIN clinical trial in mild to moderate Alzheimer’s disease patients.

Likes

Mentions

Location: United States, California, South San Francisco

Employees: 11-50

Total raised: $92M

Founded date: 2012

Facebook

Investors 5

Date	Name	Website
-	Dolby Fami...	dolbyventu...
-	Takeda Ven...	takeda.com
-	Sequoia Ca...	sequoiacap...
-	Breakout L...	breakoutla...
-	Breakout V...	breakout.v...

Funding Rounds 3

Date	Series	Amount	Investors
31.05.2018	Series B	$76M	-
17.01.2016	Series A	$15M	-
06.10.2014	Seed	$1M	-

Mentions in press and media 20

Date	Title	Description
09.12.2021	Breakout Ventures has a new, $112.5 million fund, backed by Tony Fadell, Chris Sacca and others	Breakout Ventures, a San Francisco-based seed- and Series A-stage venture firm that funds what it calls creative biosciences startups, has closed the second fund in its five-year history with $112.5 million in capital commitments. Both of i...
11.11.2021	Cortexyme CTAD 2021 Readout Roundtable Presentation	Top-line Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer's Disease Michael Detke1, Marwan Sabbagh2, Mark Ryder3, Joanna Bolger1, Dave Hennings1, Vladimir Skljarevski1, Shirin Kapur1, Debasish Rah...
14.07.2021	Cortexyme : IADR 2021 Poster Presentation "Gingipain Inhibitors Penetrate And Inhibit Gingipains In Porphyromonas gingivalis Biofilms" July 23, 2021	A) Biofilms formed from a 106 CFU/mL culture over 48 hr were treated with COR388 (1μM) for 1hr, harvested, and Kgp activity measured Various parameters were optimized including wash conditions, growth kinetics, and inoculum A&D) HA Z-st...
05.03.2021	VC Lindy Fishburne on the seemingly sudden democratization of science	Deep science investor Lindy Fishburne cofounded the seed- and early-stage venture firm Breakout Ventures several years ago, after cofounding Breakout Labs within the Thiel Foundation back in 2011, and she has amassed a wide array of stakes ...
26.01.2021	Cortexyme : Corporate Overview January 2020	January 26, 2021 Disclaimer Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and...
02.07.2018	These 50 founders and VCs suggest 2018 may be a tipping point for women in tech: Part 2	On Friday, we featured 25 founders and VCs who are having a notable 2018 — and who happen to be women. Herewith, 25 more who deserve some kudos for getting it done in the first half of this year. This list, meant to highlight the growing nu...
01.06.2018	Term Sheet — Friday, June 1	NO NEW FUND Happy Friday, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop The Conways will continue to use the SV Angel brand going forward, but they will be cutting much smaller checks — to the tune of $2...
31.05.2018	Cortexyme Completes $76M in Series B Financing	Cortexyme, Inc., a South San Francisco, CA-based clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s disease (AD) and other degenerative diseases, completed a $76m Series B financing. Backers inc...
31.05.2018	Cortexyme Nabs $76M	SOUTH SAN FRANCISCO, CA, Cortexyme today announced the completion of a $76 million Series B financing. >> Click here for more funding data on Cortexyme >> To export Cortexyme funding data to PDF and Excel, click here Cort...
31.05.2018	Cortexyme Completes $76 Million Series B Financing	-
31.05.2018	Firm targeting potential bacterial role in Alzheimer’s gets $76 million Series B	The company is developing COR388, an orally administered bacterial protease inhibitor that targets an antigen in the brains of Alzheimer’s patients that Cortexyme co-founder and Chief Scientific Officer Stephen Dominy discovered. COR388 is ...
14.09.2017	Breakout Ventures, spun out of Peter Thiel’s Breakout Labs, has closed its debut fund with $60M	Lindy Fishburne has spent most of the last six years heading up Breakout Labs, a San Francisco-based program that’s underwritten by renowned investor Peter Thiel and that in 2011 began offering nascent science-focused startups up to $350,00...
17.01.2016	Cortexyme Raises $15M in Series A Financing	Cortexyme, Inc., a South San Francisco, California-based developer of therapeutics to alter the course of Alzheimer’s and other degenerative disorders, raised $15m in Series A financing. The round was led by Pfizer Inc. new participation fr...
07.01.2016	Pre-JP Morgan VC dealapalooza: Alector, NextCure and Cortexyme raise more than $100M	Alector CEO Arnon Rosenthal The start of every new year comes with a traditional blast of biopharma deal news in the week ahead of the annual JP Morgan confab. And this year, the news flow is just a little too frenzied for it to be containe...
06.10.2014	Cortexyme Raises $1M	Cortexyme, a San Francisco CA-based healthcare technology company, raised $1m in funding. The round was led by evergreen fund Dolby Family Ventures, which invested $500k. The company intends to use the funds to continue preclinical research...
06.10.2014	Cortexyme Raises $1M Seed Round	SAN FRANCISCO, CA, Cortexyme received a $500,000 investment from Dolby Family Ventures as part of $1 million in seed financing to fund their preclinical research. >> Click here for more funding data on Cortexyme >> To export...
12.06.2014	Breakout Labs backs startups building wearable for the gut, stem cell treatment for bones	G-Tech Medical is developing a wireless, wearable patch that works like an “EKG for the gut.” The thin, disposable electrode patch would measure the electrical activity from the stomach, small intestine and colon. Physicians would use the i...
-	Firm targeting potential bacterial role in Alzheimer’s gets $76 million Series B	A company developing therapeutics for Alzheimer’s disease and other degenerative illnesses has raised $76 million in a Series B funding round. Cortexyme, based in South San Francisco, California, said Thursday that it had raised the Series ...
-	Employees at top biotech companies can get paid up to $1.6 million. Here's where workers made the most in 2021.	Photo_Concepts/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Twenty-one drug companies reported median employee pay of over $350,000 in 2021. Insider got exclusive MyLogIQ ...
-	Breakout Labs backs startups building wearable for the gut, stem cell treatment for bones	A wearable device that could transform how physicians diagnose the underlying causes of GI disorders is one of three innovative early stage life science companies Peter Thiel’s Breakout Labs is backing. The program from the Thiel Foundation...

Cortexyme, Inc.

Investors 5

Funding Rounds 3

Mentions in press and media 20

Reviews 0